Chronic spontaneous urticaria market seen reaching $3.21 billion by 2030
The chronic spontaneous urticaria market is projected to rise from $2.23 billion in 2025 to $3.21 billion by 2030, driven by broader treatment use, rising awareness and more biologic development. North America led the market in 2025, while the report points to stronger long-term demand for maintenance therapies and targeted monoclonal antibodies.
Why it matters: - Chronic spontaneous urticaria is a persistent skin condition that can require long-term treatment, so market growth reflects rising demand for ongoing care options. - The forecast points to stronger use of biologics, antihistamines and maintenance therapies, which could expand treatment access for patients with more severe or recurring symptoms. - The report also signals where research and drug development money may flow next, especially in autoimmune dermatology and targeted therapies.
What happened: - The Business Research Company released its Chronic Spontaneous Urticaria Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The chronic spontaneous urticaria market is estimated at $2.23 billion in 2025 and is projected to reach $2.41 billion in 2026. - The market is forecast to grow to $3.21 billion by 2030. - The report cites a 2025-to-2026 compound annual growth rate of 8.4% and a 2026-to-2030 CAGR of 7.4%. - North America was the largest regional market in 2025. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company published a free sample report and the full market report online: Download the sample report and View the full report.
The details: - Chronic spontaneous urticaria, or CSU, involves recurring hives and angioedema that last longer than six weeks without an obvious external cause. - The condition is believed to involve an autoimmune response in which the immune system attacks healthy skin tissue. - Standard treatment focuses on antihistamines, while biologics and other drugs are used for more severe or persistent cases. - Historical growth has been supported by rising chronic skin allergies, wider access to second-generation antihistamines, improved diagnostic techniques, more dermatology clinic visits and higher patient awareness. - The report says future growth will be supported by new biologic drugs, more investment in autoimmune dermatology research, broader use of targeted monoclonal antibodies, stronger focus on symptom-free disease management and growing adoption of long-term maintenance therapies. - Anticipated market trends include more biologic treatment use, advanced antihistamine regimens, deeper insight into autoimmune mechanisms, personalized treatment plans and better monitoring for sustained disease control. - Alcohol consumption is identified as a market driver because it can worsen CSU symptoms in some patients by triggering more frequent or severe hives and swelling episodes. - The release cites a 2025 Priory Group survey showing 25% of UK adults aged 18 to 24 abstain from alcohol entirely.
Between the lines: - The market outlook suggests CSU is moving from symptom treatment toward more specialized long-term disease management. - The emphasis on biologics and monoclonal antibodies suggests higher-value therapies may take a larger role as diagnosis and awareness improve. - The alcohol finding shows how lifestyle factors can influence both symptom burden and demand for treatment. - Regional leadership by North America likely reflects stronger diagnosis rates, treatment access and healthcare infrastructure compared with some other markets.
What's next: - Drug makers and dermatology-focused researchers are likely to keep pushing biologic and targeted therapy development. - The market will probably track adoption of long-term maintenance regimens and newer personalized treatment approaches. - Regional growth will depend on patient awareness, diagnostic capacity and access to advanced therapies. - The report says its 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and updated graphics and tables.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Healthy Living Europe
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.